

References

- 1 Weston R. Whooping cough: a brief history to the 19th century. *Can Bull Med Hist* 2012;29:329-349. doi: 10.3138/cbmh.29.2.329.
- 2 Diavatopoulos DA, Cummings CA, Schouls LM, Brinig MM, Relman DA, Mooi FR. *Bordetella pertussis*, the causative agent of whooping cough, evolved from a distinct, human-associated lineage of *B. bronchiseptica*. *PLoS Pathog* 2005;1:e45. Epub 2005 Dec 30.
- 3 Aslanabadi A, Ghabili K, Shad K, Khalili M, Sajadi MM. Emergence of whooping cough: notes from three early epidemics in Persia. *Lancet Infect Dis* 2015;15:1480-4. doi: 10.1016/S1473-3099(15)00292-3. Epub 2015 Aug 19.
- 4 Holmes WH: *Bacillary and Rickettsial Infections, Acute and Chronic: A Textbook: Black Death to White Plague*. New York, Macmillan, 1940.
- 5 Hardy A. Whooping cough. In Kiple KF (ed): *The Cambridge World History of Human Disease*. New York, Cambridge University Press, 1993. pp 1094–1096.
- 6 Clark TA. Changing pertussis epidemiology: everything old is new again. *J Infect Dis* 2014;209:978-981.
- 7 Heininger U, Klich K, Stehr K, et al. Clinical findings in *Bordetella pertussis* infections: results of a prospective multicenter surveillance study. *Pediatrics* 1997;100:E10.
- 8 Paddock CD, Sanden GN, Cherry JD, et al. Pathology and pathogenesis of fatal *Bordetella pertussis* infection in infants. *Clin Infect Dis* 2008;47:328–338.
- 9 Halasa NB, Barr FE, Johnson JE, et al. Fatal pulmonary hypertension associated with pertussis in infants: does extracorporeal membrane oxygenation have a role? *Pediatrics* 2003;112:1274–1278.

- 10 Williams GD, Numa A, Sokol J, et al. ECLS in pertussis: does it have a role? *Intensive Care Med* 1998;24:1089–1092.
- 11 Wortis N, Strebel PM, Wharton M, et al. Pertussis deaths: report of 23 cases in the United States, 1992 and 1993. *Pediatrics* 1996;97:607–612.
- 12 Sreenan CD, Osioviich H. Neonatal pertussis requiring extracorporeal membrane oxygenation. *Pediatr Surg Int* 2001;17:201–203.
- 13 Chan L. Cough and respiratory distress in a two-month-old infant. *Pediatr Infect Dis J* 1997;16:631–635.
- 14 Gillis J, Grattan-Smith T, Kilham H. Artificial ventilation in severe pertussis. *Arch Dis Child* 1988;63:364–367.
- 15 Goulin GD, Kaya KM, Bradley JS. Severe pulmonary hypertension associated with shock and death in infants infected with *Bordetella pertussis*. *Crit Care Med* 1993;21:1791–1794.
- 16 Pierce C, Klein N, Peters M. Is leukocytosis a predictor of mortality in severe pertussis infection? *Intensive Care Med* 2000;26:1512–1514.
- 17 Centers for Disease Control and Prevention. Pertussis deaths: United States 2000. *MMWR Morb Mortal Wkly Rep* 2002;51:616–618.
- 18 Johnston ID, Bland JM, Ingram D, et al. Effect of whooping cough in infancy on subsequent lung function and bronchial reactivity. *Am Rev Respir Dis* 1986;134:270–275.
- 19 Olsen M, Thygesen SK, Østergaard JR, et al. Hospital-diagnosed pertussis infection in children and long-term risk of epilepsy. *JAMA* 2015;314:1844–1849.

- 20 Centers for Disease Control and Prevention. Clinical complications: infants and children. Available at <http://www.cdc.gov/pertussis/clinical/complications.html>. Accessed April 25, 2020.
- 21 Zellweger H. Pertussis encephalopathy. *Arch Pediatr* 1959;76:381–386.
- 22 Grant CC, McKay EJ, Simpson A, et al. Pertussis encephalopathy with high cerebrospinal fluid antibody titers to pertussis toxin and filamentous hemagglutinin. *Pediatrics* 1998;102(4 pt 1):986–990.
- 23 Mulholland EK: Pertussis. In Mabey D, Gill G, Weber MV, et al (eds): *Principles of Medicine in Africa*. Cambridge, Cambridge University Press, 2013, p 147.
- 24 World Health Organization. International travel and health: pertussis. Available at <http://who.int/ith/diseases/pertussis/en/>. Accessed April 25, 2020.
- 25 Senzilet LD, Halperin SA, Spika JS, et al. Pertussis is a frequent cause of prolonged cough illness in adults and adolescents. *Clin Infect Dis* 2001; 32:1691–7.
- 26 Postels-Multani S, Schmitt HJ, Wirsing von König CH, et al. Symptoms and complications of pertussis in adults. *Infection* 1995;23:139–142.
- 27 Lee GM, Lett S, Schauer S, et al. Societal costs and morbidity of pertussis in adolescents and adults. *Clin Infect Dis* 2004;39:1572-80.
- 28 Eidlitz-Markus T, Zeharia A. Bordetella pertussis as a trigger of migraine without aura. *Pediatr Neurol* 2005;33:283–284.
- 29 Skowronski DM, Buxton JA, Hestrin M, et al. Carotid artery dissection as a possible severe complication of pertussis in an adult: clinical case report and review. *Clin Infect Dis* 2003;36:e1–4.

- 30 Jenkins P, Clarke SW. Cough syncope: a complication of adult whooping cough. *Br J Dis Chest* 1981;75:311–313.
- 31 Halperin SA, Marrie TJ. Pertussis encephalopathy in an adult: case report and review. *Rev Infect Dis* 1991;13:1043–1047.
- 32 MacLean DW. Adults with pertussis. *J R Coll Gen Pract* 1982;32:298–300.
- 33 Broder KR, Cortese MM, Iskander JK, et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep* 2006;55(RR-3):1–34.
- 34 Centers for Disease Control and Prevention. Fatal case of unsuspected pertussis diagnosed from a blood culture: Minnesota, 2003. *MMWR Morb Mortal Wkly Rep* 2004;53:131–132.
- 35 Mertens PL, Borsboom GJ, Richardus JH. A pertussis outbreak associated with social isolation among elderly nuns in a convent. *Clin Infect Dis* 2007;44:266–268.
- 36 Cherry J, Brunnel P, Golden G. Report of the Task Force on Pertussis and Pertussis Immunization, 1988. *Pediatrics* 1988;81(Suppl.):933–984.
- 37 Schmitt-Grohe S, Cherry JD, Heininger U, et al. Pertussis in German adults. *Clin Infect Dis* 1995;21:860–866.
- 38 Mink CM, Cherry JD, Christenson P, et al. A search for *Bordetella pertussis* infection in university students. *Clin Infect Dis* 1992;14:464–471.
- 39 Baughman AL, Bisgard KM, Edwards KM, et al. Establishment of diagnostic cutoff points for levels of serum antibodies to pertussis toxin, filamentous hemagglutinin, and

- fimbriae in adolescents and adults in the United States. *Clin Diagn Lab Immunol* 2004;11:1045–1053.
- 40 Strebel P, Nordin J, Edwards K, et al. Population-based incidence of pertussis among adolescents and adults, Minnesota, 1995–1996. *J Infect Dis* 2001;183:1353–1359.
- 41 Cherry JD, Beer T, Chartrand SA, et al. Comparison of values of antibody to *Bordetella pertussis* antigens in young German and American men. *Clin Infect Dis* 1995;20:127–1274,.
- 42 Rosenthal S, Strebel P, Cassidy P, et al. Pertussis infection among adults during the 1993 outbreak in Chicago. *J Infect Dis* 1995;171:1650–1652.
- 43 Robertson PW, Goldberg H, Jarvie BH, et al. *Bordetella pertussis* infection: a cause of persistent cough in adults. *Med J Aust* 1987;146:522–525.
- 44 Wright SW, Edwards KM, Decker MD, et al. Pertussis infection in adults with persistent cough. *JAMA* 1995;273:1044–1046.
- 45 Nennig ME, Shinefield HR, Edwards KM, et al. Prevalence and incidence of adult pertussis in an urban population. *JAMA* 1996;275:1672–1674.
- 46 Centers for Disease Control and Prevention. Pertussis: United States, 1997–2000. *MMWR Morb Mortal Wkly Rep* 2002;51:73–76.
- 47 Guris D, Strebel PM, Bardenheier B, et al. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990–1996. *Clin Infect Dis* 1999;28:1230–1237.
- 48 National Immunization Program, Bacterial Vaccine Preventable Diseases Branch. Pertussis Surveillance Report, August 6, 2004.

49. World Health Organization. Pertussis global annual reported cases and DTP3 coverage 1980-2018. Available at https://www.who.int/immunization/monitoring_surveillance/burden/vpd/surveillance_type/passive/pertussis_coverage_2018.jpg?ua=1. Accessed July 18, 2020.
50. Chitkara AJ, Pujadas Ferrer M, Forsyth K, et al. Pertussis vaccination in mixed markets: Recommendations from the Global Pertussis Initiative. *Int J Infect Dis* 2020;96:482-488. doi:10.1016/j.ijid.2020.04.081.
51. Mosser JF, Gagne-Maynard W, Rao PC, et al. Mapping diphtheria-pertussis-tetanus vaccine coverage in Africa, 2000-2016: a spatial and temporal modelling study. *Lancet*. 2019;393:1843-1855. doi:10.1016/S0140-6736(19)30226-0.
52. Son S, Thamlikitkul V, Chokephaibulkit K, et al. Prospective multinational serosurveillance study of *Bordetella pertussis* infection among 10- to 18-year-old Asian children and adolescents. *Clin Microbiol Infect*. 2019;25:250.e1-250.e7. doi:10.1016/j.cmi.2018.04.013.
53. Thisyakorn U, Tantawichien T, Thisyakorn C, Buchy P. Pertussis in the Association of Southeast Asian Nations: epidemiology and challenges. *Int J Infect Dis*. 2019;87:75-83. doi:10.1016/j.ijid.2019.07.016.
54. Pneumonia Etiology Research for Child Health (PERCH) Study Group. Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study [published correction appears in *Lancet*. 2019 Aug 31;394(10200):736]. *Lancet*. 2019;394:757-779. doi:10.1016/S0140-6736(19)30721-4.

- 55 Octavia S, Sintchenko V, Gilbert GL, et al. Newly emerging clones of *Bordetella pertussis* carrying *prn2* and *ptxP3* alleles implicated in Australian pertussis epidemic in 2008-2010. *J Infect Dis* 2012;205:1220–1224.
- 56 Weber C, Boursaux-Eude C, Coralie G, et al. Polymorphism of *Bordetella pertussis* isolates circulating for the last 10 years in France, where a single effective whole-cell vaccine has been used for more than 30 years. *J Clin Microbiol* 2001;39:4396–4403.
- 57 King AJ, Berbers G, van Oirschot HF, et al. Role of the polymorphic region 1 of the *Bordetella pertussis* protein pertactin in immunity. *Microbiology* 2001;147:2885–2895.
- 58 Mooi FR, van Loo IH, King AJ. Adaptation of *Bordetella pertussis* to vaccination: a cause for its reemergence? *Emerg Infect Dis* 2001;7(3 Suppl.):526–528.
- 59 Hallander HO, Advani A, Donnelly D, et al. Shifts of *Bordetella pertussis* variants in Sweden from 1970 to 2003, during three periods marked by different vaccination programs. *J Clin Microbiol* 2005;43:2856–2865.
- 60 Bouchez V, Brun D, Cantinelli T, et al. First report and detailed characterization of *B. pertussis* isolates not expressing pertussis toxin or pertactin. *Vaccine* 2009;27:6034–6041.
- 61 Lam C, Octavia S, Ricafort L, et al. Rapid increase in pertactin-deficient *Bordetella pertussis* isolates, Australia. *Emerg Infect Dis* 2014;20:626-633.
- 62 Hegerle N, Dore G, Guiso N. Pertactin deficient *Bordetella pertussis* present a better fitness in mice immunized with an acellular pertussis vaccine. *Vaccine* 2014;32:6597-6600.

- 63 Zeddeman A, van Gent M, Heuvelman CJ, et al. Investigations into the emergence of pertactin-deficient *Bordetella pertussis* isolates in six European countries, 1996 to 2012. *Euro Surveill* 2014;19:20881.
- 64 Pawloski LC, Queenan AM, Cassiday PK, et al. Prevalence and molecular characterization of pertactin-deficient *Bordetella pertussis* in the United States. *Clin Vaccine Immunol* 2014;21:119-125.
- 65 Martin SW, Pawloski L, Williams M, et al. Pertactin-negative *Bordetella pertussis* strains: evidence for a possible selective advantage. *Clin Infect Dis* 2015;60:223-227.
- 66 Weigand MR, Williams MM, Peng Y, Kania D, Pawloski LC, Tondella ML; CDC Pertussis Working Group. Genomic Survey of *Bordetella pertussis* Diversity, United States, 2000-2013. *Emerg Infect Dis* 2019;25:780-783. doi: 10.3201/eid2504.180812.
- 67 Breakwell L, Kelso P, Finley C, et al. Pertussis vaccine effectiveness in the setting of pertactin-deficient pertussis. *Pediatrics* 2016;137:e20153973.
- 68 Tuomanen E: *Bordetella pertussis* adhesins. In: Wardlaw AC, Parton R (eds): *Pathogenesis and Immunity in Pertussis*. New York, John Wiley & Sons, 1988, pp 75–94.
- 69 Tuomanen E, Weiss A, Rich R, et al. Filamentous hemagglutinin and pertussis toxin promote adherence of *Bordetella pertussis* to cilia. *Dev Biol Stand* 1985;61:197–204.
- 70 Brennan MJ, Li ZM, Cowell JL, et al. Identification of a 69-kilodalton nonfimbrial protein as an agglutinin of *Bordetella pertussis*. *Infect Immun* 1988;56:3189–3195.
- 71 Hewlett EL. Pertussis: current concepts of pathogenesis and prevention. *Pediatr Infect Dis J* 1997;16(4 Suppl.):S78–84.
- 72 Weiss A. Mucosal immune defenses and the response of *Bordetella pertussis*. *ASM News* 1997;63:22–28.

- 73 Zhang JM, Cowell JL, Steven AC, et al. Purification of serotype 2 fimbriae of *Bordetella pertussis* and their identification as a mouse protective antigen. *Dev Biol Stand* 1985;61:173–185.
- 74 de Gouw D, Diavatopoulos DA, Bootsma HJ, et al. Pertussis: a matter of immune modulation. *FEMS Microbiol Rev* 2011;35:441–474.
- 75 Melvin JA, Scheller EV, Miller JF, et al. *Bordetella pertussis* pathogenesis: current and future challenges. *Nat Rev Microbiol* 2014;12:274-288.
- 76 Warfel JM, Beren J, Kelly VK, et al. Nonhuman primate model of pertussis. *Infect Immun* 2012;80:1530-1536.
- 77 Warfel JM, Beren J, Merkel TJ. Airborne transmission of *Bordetella pertussis*. *J Infect Dis* 2012;206:902-906.
- 78 Warfel JM, Zimmerman LI, Merkel TJ. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. *Proc Natl Acad Sci USA* 2014;111:787-792.
- 79 Long SS, Welkon CJ, Clark JL. Widespread silent transmission of pertussis in families: antibody correlates of infection and symptomatology. *J Infect Dis* 1990;161:480–486.
- 80 Waters V, Jamieson F, Richardson SE, et al. Outbreak of atypical pertussis detected by polymerase chain reaction in immunized preschool-aged children. *Pediatr Infect Dis J* 2009;28:582–587.
- 81 Klement E, Uliel L, Engel I, et al. An outbreak of pertussis among young Israeli soldiers. *Epidemiol Infect* 2003;131:1049–1054.

- 82 Zhang Q, Yin Z, Li Y, Luo H, et al. Prevalence of asymptomatic *Bordetella pertussis* and *Bordetella parapertussis* infections among school children in China as determined by pooled real-time PCR: a cross-sectional study. *Scand J Infect Dis* 2014;46:280-287.
- 83 Srugo I, Benilevi D, Madeb R, et al. Pertussis infection in fully vaccinated children in day-care centers, Israel. *Emerg Infect Dis* 2000;6:526–529.
- 84 Fisher MC, Long SS, McGowan KL, et al. Outbreak of pertussis in a residential facility for handicapped people. *J Pediatr* 1989;114:934–939.
- 85 Craig R, Kunkel E, Crowcroft NS, et al. Asymptomatic Infection and Transmission of Pertussis in Households: A Systematic Review. *Clin Infect Dis* 2020;70:152-161. doi: 10.1093/cid/ciz531.
- 86 Broome CV, Fraser DW, English WJ: Pertussis: diagnostic methods and surveillance. In Manclark CR, Hill JC (eds): International Symposium on Pertussis. Bethesda, MD, US Department of Health, Education, and Welfare, Public Health Service, National Institutes of Health, DHEW publication no. (NIH)79-1830:19–22. 1979.
- 87 Strebel PM, Cochi SL, Farizo KM, et al. Pertussis in Missouri: evaluation of nasopharyngeal culture, direct fluorescent antibody testing, and clinical case definitions in the diagnosis of pertussis. *Clin Infect Dis* 1993;16:276–285.
- 88 Onorato IM, Wassilak SG. Laboratory diagnosis of pertussis: the state of the art. *Pediatr Infect Dis J* 1987;6:145–151.
- 89 Halperin SA, Bortolussi R, Wort AJ. Evaluation of culture, immunofluorescence, and serology for the diagnosis of pertussis. *J Clin Microbiol* 1989;27:752–757.
- 90 Hallander HO, Reizenstein E, Renemar B, et al. Comparison of nasopharyngeal aspirates with swabs for culture of *Bordetella pertussis*. *J Clin Microbiol* 1993;31:50–52.

- 91 Cattaneo LA, Reed GW, Haase DH, et al. The seroepidemiology of *Bordetella pertussis* infections: a study of persons ages 1–65 years. *J Infect Dis* 1996;173:1256–1259.
- 92 Jõgi P, Oona M, Toompere K, et al. Seroprevalence of IgG antibodies to pertussis toxin in children and adolescents in Estonia. *Vaccine* 2014;32:5311-5315.
- 93 Zhang Q, Zheng H, Liu M, et al. The seroepidemiology of immunoglobulin G antibodies against pertussis toxin in China: a cross sectional study. *BMC Infect Dis* 2012;12:138.
- 94 Rendi-Wagner P, Tobias J, Moerman L, et al. The seroepidemiology of *Bordetella pertussis* in Israel--Estimate of incidence of infection. *Vaccine* 2010;28:3285-3290.
- 95 Wang CQ, Zhu QR. Seroprevalence of *Bordetella pertussis* antibody in children and adolescents in China. *Pediatr Infect Dis J* 2011;30:593-596.
- 96 Mossong J, Putz L, Shkedy Z, et al. Seroepidemiology of diphtheria and pertussis in Luxembourg in 2000. *Epidemiol Infect* 2006;134:573-578.
- 97 Giammanco A, Chiarini A, Stroffolini T, et al. Seroepidemiology of pertussis in Italy. *Rev Infect Dis* 1991;13:1216–1220.
- 98 Cherry JD, Chang SJ, Klein D, et al. Prevalence of antibody to *Bordetella pertussis* antigens in serum specimens obtained from 1793 adolescents and adults. *Clin Infect Dis* 2004;39:1715–1718.
- 99 de Greeff SC, de Melker HE, van Gageldonk PG, et al. Seroprevalence of pertussis in the Netherlands: evidence for increased circulation of *Bordetella pertussis*. *PLoS One* 2010;5:e14183.
- 100 Halperin SA, Bortolussi R, MacLean D, et al. Persistence of pertussis in an immunized population: results of the Nova Scotia Enhanced Pertussis Surveillance Program. *J Pediatr* 1989;115:686–693.

- 101 Steketee RW, Burstyn DG, Wassilak SG, et al. A comparison of laboratory and clinical methods for diagnosing pertussis in an outbreak in a facility for the developmentally disabled. *J Infect Dis* 1988;157:441–449.
- 102 Addiss DG, Davis JP, Meade BD, et al. A pertussis outbreak in a Wisconsin nursing home. *J Infect Dis* 1991;164:704–710.
- 103 Marchant CD, Loughlin AM, Lett SM, et al. Pertussis in Massachusetts, 1981–1991: incidence, serologic diagnosis, and vaccine effectiveness. *J Infect Dis* 1994;169:1297–1305.
- 104 Centers for Disease Control and Prevention. Pertussis (whooping cough) diagnostic testing. Available at <https://www.cdc.gov/pertussis/clinical/diagnostic-testing/index.html>. Accessed April 25, 2020.
- 105 Yih WK, Lett SM, des Vignes FN, et al. The increasing incidence of pertussis in Massachusetts adolescents and adults, 1989–1998. *J Infect Dis* 2000;182:1409–1416.
- 106 de Melker HE, Versteegh FG, Conyn-Van Spaendonck MA, et al. Specificity and sensitivity of high levels of immunoglobulin G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with *Bordetella pertussis*. *J Clin Microbiol* 2000;38:800–806.
- 107 Wirsing von König CH, Schmitt HJ, Bogaerts H, et al. Factors influencing the analysis of secondary prevention of pertussis. *Dev Biol Stand* 1997;89:175–179.
- 108 De Serres G, Boulianne N, Duval B. Field effectiveness of erythromycin prophylaxis to prevent pertussis within families. *Pediatr Infect Dis J* 1995;14:969–975.
- 109 Winter K, Zipprich J, Harriman K, et al. Risk factors associated with infant deaths from pertussis: a case-control study. *Clin Infect Dis* 2015;61:1099-1106.

- 110 Tiwari T, Murphy TV, Moran J. Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis: 2005 CDC Guidelines. *MMWR Recomm Rep* 2005;54(RR-14):1–16.
- 111 Kimberlin DW, Brady MT, Jackson MA, et al, eds. *Red book: 2015 report of the Committee on Infectious Diseases*. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2015.
- 112 Halperin SA, Bortolussi R, Langley JM, et al. Seven days of erythromycin estolate is as effective as fourteen days for the treatment of *Bordetella pertussis* infections. *Pediatrics* 1997;100:65–71.
- 113 Bass JW, Klenk EL, Kotheimer JB, et al. Antimicrobial treatment of pertussis. *J Pediatr* 1969;75:768–781.
- 114 Hewlett EL: *Bordetella* species. In Mandell G (ed): *Douglas and Bennett's Principles and Practice of Infectious Diseases*. 4th ed. New York, Churchill Livingstone, 1995.
- 115 Mortimer Jr EA, Jones PK. An evaluation of pertussis vaccine. *Rev Infect Dis* 1979;1:927–934.
- 116 Kawai H, Aoyama T, Goto A, et al. Evaluation of pertussis treatment with erythromycin ethylsuccinate and stearate according to age. *Kansenshogaku Zasshi* 1994;68:1324–1329.
- 117 Aoyama T, Sunakawa K, Iwata S, et al. Efficacy of short-term treatment of pertussis with clarithromycin and azithromycin. *J Pediatr* 1996;129:761–764.
- 118 Halperin SA, Bortolussi R, Langley JM, et al. A randomized, placebo-controlled trial of erythromycin estolate chemoprophylaxis for household contacts of children with culture-positive *Bordetella pertussis* infection. *Pediatrics* 1999;104:e42.

- 119 Bortolussi R, Miller B, Ledwith M, et al. Clinical course of pertussis in immunized children. *Pediatr Infect Dis J* 1995;14:870–874.
- 120 Li L, Deng J, Ma X, et al. High Prevalence of Macrolide-Resistant *Bordetella pertussis* and ptxP1 Genotype, Mainland China, 2014-2016. *Emerg Infect Dis* 2019; 25:2205-14.
- 121 Kwantes W, Joynson DH, Williams WO. *Bordetella pertussis* isolation in general practice: 1977–79 whooping cough epidemic in West Glamorgan. *J Hyg (Lond)* 1983;90:149–158.
- 122 Henry R, Dorman D, Skinner J, et al. Limitations of erythromycin in whooping cough. *Med J Aust* 1981;2:108–109.
- 123 Beneson AS. *Control of Communicable Disease Manual*. 16th ed. Washington, DC: American Public Health Association; 1995.
- 124 Madsen T. Vaccination against whooping cough. *JAMA* 1933;101:187–188.
- 125 Kendrick P, Eldering G. Progress report on pertussis immunization. *Am J Public Health* 1936;26:8–12.
- 126 Schmitt HJ, von Konig CH, Neiss A, et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. *JAMA* 1996;275:37–41.
- 127 Liese JG, Meschievitz CK, Harzer E, et al. Efficacy of a two-component acellular pertussis vaccine in infants. *Pediatr Infect Dis J* 1997;16:1038–1044.
- 128 Ramsay ME, Farrington CP, Miller E. Age-specific efficacy of pertussis vaccine during epidemic and non-epidemic periods. *Epidemiol Infect* 1993;111:41–48.
- 129 Gustafsson L, Hallander HO, Olin P, et al. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. *N Engl J Med* 1996;334:349–355.

- 130 Greco D, Salmaso S, Mastrantonio P, et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. *N Engl J Med* 1996;334:341–348.
- 131 Simondon F, Preziosi MP, Yam A, et al. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. *Vaccine* 1997;15:1606–1612.
- 132 Kanai K. Japan's experience in pertussis epidemiology and vaccination in the past thirty years. *Jpn J Med Sci Biol* 1980;33:107–143.
- 133 Kimura M, Kuno-Sakai H. Immunization system in Japan: its history and present situation. *Acta Paediatr Jpn* 1988;30:109–126.
- 134 Sato Y, Kimura M, Fukumi H. Development of a pertussis component vaccine in Japan. *Lancet* 1984;1:122–126.
- 135 Cherry JD. The epidemiology of pertussis and pertussis immunization in the United Kingdom and the United States: a comparative study. *Curr Probl Pediatr* 1984;14:1–78.
- 136 Stuart-Harris CH: Experiences of pertussis in the United Kingdom. In Manclark CR, Hill JC (eds): *International Symposium on Pertussis*. Washington, DC, US Department of Health, Education, and Welfare, publication (NIH) 79-1830, 1979.
- 137 Romanus V, Jonsell R, Bergquist SO. Pertussis in Sweden after the cessation of general immunization in 1979. *Pediatr Infect Dis J* 1987;6:364–671.
- 138 Storsaeter J, Olin P. Relative efficacy of two acellular pertussis vaccines during three years of passive surveillance. *Vaccine* 1992;10:142–144.
- 139 Taranger J, Trollfors B, Bergfors E, et al. Immunologic and epidemiologic experience of vaccination with a monocomponent pertussis toxoid vaccine. *Pediatrics* 2001;108:E115.

- 140 Onorato IM, Wassilak SG, Meade B. Efficacy of whole-cell pertussis vaccine in preschool children in the United States. *JAMA* 1992;267:2745–2749.
- 141 Vesselinova-Jenkins CK, Newcombe RG, Gray OP, et al. The effects of immunisation upon the natural history of pertussis: a family study in the Cardiff area. *J Epidemiol Community Health* 1978;32:194–199.
- 142 Grob PR, Crowder MJ, Robbins JF. Effect of vaccination on severity and dissemination of whooping cough. *Br Med J (Clin Res Ed)* 1981;282:1925–1928.
- 143 Preziosi MP, Halloran ME. Effects of pertussis vaccination on disease: vaccine efficacy in reducing clinical severity. *Clin Infect Dis* 2003;37:772–779.
- 144 Preziosi MP, Halloran ME. Effects of pertussis vaccination on transmission: vaccine efficacy for infectiousness. *Vaccine* 2003;21:1853–1861.
- 145 McNamara LA, Skoff T, Faulkner A, et al. Reduced Severity of Pertussis in Persons With Age-Appropriate Pertussis Vaccination-United States, 2010-2012. *Clin Infect Dis* 2017;65:811-818. doi: 10.1093/cid/cix421.
- 146 Centers for Disease Control and Prevention. Diphtheria, tetanus, and pertussis: recommendations for vaccine use and other preventive measures. Recommendations of the Immunization Practices Advisory Committee (ACIP). *MMWR Recomm Rep* 1991;40(RR-10):1–28.
- 147 Prymula R, Siegrist CA, Chlibek R, et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. *Lancet* 2009;374:1339-1350.
- 148 Cadoz M, Arminjon F, Quentin-Millet MJ: Safety and immunogenicity of Merieux acellular pertussis in adult volunteers. In Transcript of the Workshop on Acellular

- Pertussis Vaccines. Washington, DC, US Department of Health and Human Services, 1986, pp 131–134.
- 149 Cody CL, Baraff LJ, Cherry JD, et al. Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. *Pediatrics* 1981;68:650–660.
- 150 Decker MD, Edwards KM, Steinhoff MC, et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. *Pediatrics* 1995;96:557–566.
- 151 Baraff LJ, Cody CL, Cherry JD. DTP-associated reactions: an analysis by injection site, manufacturer, prior reactions, and dose. *Pediatrics* 1984;73:31–36.
- 152 Berkovic SF, Harkin L, McMahon JM, et al. De-novo mutations of the sodium channel gene SCN1A in alleged vaccine encephalopathy: a retrospective study. *Lancet Neurol* 2006;5:488-492.
- 153 Reyes IS, Hsieh DT, Laux LC, et al. Alleged cases of vaccine encephalopathy rediagnosed years later as Dravet syndrome. *Pediatrics* 2011;128:e699-702.
- 154 Howson CP, Fineberg HV. Adverse events following pertussis and rubella vaccines: summary of a report of the Institute of Medicine. *JAMA* 1992;267:392–396.
- 155 DPT Vaccine and Chronic Nervous System Dysfunction: A New Analysis. Institute of Medicine (US) Committee to Study New Research on Vaccines; Stratton KR, Howe CJ, Johnston RB Jr., editors. Washington (DC): National Academies Press (US); 1994.
- 156 Geraghty K. Presentation to the Immunization Practices Advisory Committee, Centers for Disease Control and Prevention. Atlanta, GA, October 25, 1985.
- 157 Howson CP, Fineberg HV. The ricochet of magic bullets: summary of the Institute of Medicine Report, Adverse Effects of Pertussis and Rubella Vaccines. *Pediatrics* 1992;89:318–324.

- 158 Kimura M, Hikino N. Results with a new DTP vaccine in Japan. *Dev Biol Stand* 1985;61:545–561.
- 159 Aoyama T, Murase Y, Gonda T, et al. Type-specific efficacy of acellular pertussis vaccine. *Am J Dis Child* 1988;142:40–42.
- 160 Kimura M, Kuno-Sakai H. Current epidemiology of pertussis in Japan. *Pediatr Infect Dis J* 1990;9:705–709.
- 161 Noble GR, Bernier RH, Esber EC, et al. Acellular and whole-cell pertussis vaccines in Japan: report of a visit by US scientists. *JAMA* 1987;257:1351–1356.
- 162 Kimura M. Japanese clinical experiences with acellular pertussis vaccines. *Dev Biol Stand* 1991;73:5–9.
- 163 Kuno-Sakai H, Kimura M. Safety and efficacy of acellular pertussis vaccine in Japan, evaluated by 23 years of its use for routine immunization. *Pediatr Int* 2004;46:650–655.
- 164 Okada K, Ohashi Y, Matsuo F, et al. Effectiveness of an acellular pertussis vaccine in Japanese children during a non-epidemic period: a matched case-control study. *Epidemiol Infect* 2009;137:124-130.
- 165 Ohfuji S, Okada K, Nakano T, et al. Effectiveness of acellular pertussis vaccine in a routine immunization program: a multicenter, case-control study in Japan. *Vaccine* 2015;33:1027-1032.
- 166 Klein DL. Multicenter acellular pertussis vaccine trial: a National Institutes of Health perspective. *Pediatrics* 1995;96 (Pt 2):547-8.
- 167 Edwards KM, Meade BD, Decker MD, et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. *Pediatrics* 1995;96:548–557.

- 168 Edwards KM, Decker MD. Pertussis Vaccine. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM, eds. *Vaccines*, 7th ed. Philadelphia: Elsevier, 2017:711-761.
- 169 Placebo-controlled trial of two acellular pertussis vaccines in Sweden: protective efficacy and adverse events. Ad Hoc Group for the Study of Pertussis Vaccines. *Lancet* 1988;1:955–960.
- 170 Storsaeter J, Olin P, Renemar B, et al. Mortality and morbidity from invasive bacterial infections during a clinical trial of acellular pertussis vaccines in Sweden. *Pediatr Infect Dis J* 1988;7:637–645.
- 171 Blackwelder WC, Storsaeter J, Olin P, et al. Acellular pertussis vaccines. Efficacy and evaluation of clinical case definitions. *Am J Dis Child* 1991;145:1285–1289.
- 172 Olin P, Storsaeter J. Vaccine efficacy in a clinical trial of acellular pertussis vaccines in Sweden: technical report. Stockholm, Sweden, National Bacteriological Laboratory, 1988.
- 173 Storsaeter J, Hallander H, Farrington CP, et al. Secondary analyses of the efficacy of two acellular pertussis vaccines evaluated in a Swedish phase III trial. *Vaccine* 1990;8:457–461.
- 174 Trollfors B, Taranger J, Lagergard T, et al. A placebo-controlled trial of a pertussis-toxoid vaccine. *N Engl J Med* 1995;333:1045–1050.
- 175 Ciofi degli Atti ML, Olin P. Severe adverse events in the Italian and Stockholm I pertussis vaccine clinical trials. *Dev Biol Stand* 1997;89:77–81.
- 176 Sanofi Pasteur. Tripedia® package insert. Available at <https://www.vaccineshoppe.com/assets/pdf/tripedia.pdf>. Accessed April 25, 2020.

- 177 Stehr K, Cherry JD, Heininger U, et al. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. *Pediatrics* 1998;101:1–11.
- 178 Taranger J, Trollfors B, Bergfors E, et al. Mass vaccination of children with pertussis toxoid—decreased incidence in both vaccinated and nonvaccinated persons. *Clin Infect Dis* 2001;33:1004–1010.
- 179 Trollfors B, Dotevall L, Sundh V, et al. Pertussis after end of a mass vaccination project: end of the “vaccination honey-moon”. *Vaccine* 2011;29:2444–2450.
- 180 Public Health Agency of Sweden. Pertussis surveillance in Sweden: twenty year report. Available at <https://www.folkhalsomyndigheten.se/contentassets/14d7068f02604bb496a319895fd9ad47/pertussis-sweden-twenty-year-report-18068.pdf>. Accessed April 25, 2020.
- 181 Gustafsson L, Hallander H, Olin P. Pertussis surveillance in Sweden: progress report Oct 1997-Sept 2004 with executive summary: seven year report. Stockholm, Swedish Institute for Infectious Disease Control (SMI), 2005.
- 182 Gustafsson L, Hessel L, Storsaeter J, et al. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age. *Pediatrics* 2006;118:978–984.
- 183 Thierry-Carstensen B, Dalby T, Stevner MA, Robbins JB, Schneerson R, Trollfors B. Experience with monocomponent acellular pertussis combination vaccines for infants, children, adolescents and adults—a review of safety, immunogenicity, efficacy and effectiveness studies and 15 years of field experience. *Vaccine* 2013; 31:5178-91.

- 184 Tiwari TS, Baughman AL, Clark TA. First pertussis vaccine dose and prevention of infant mortality. *Pediatrics*. 2015 Jun;135(6):990-9. doi: 10.1542/peds.2014-2291. Epub 2015 May 4.
- 185 Olin P, Gustafsson L, Rasmussen F. Efficacy trial of acellular pertussis vaccines: technical report trial II, with results of preplanned analysis of efficacy and immunogenicity and safety. Stockholm, Sweden, Swedish Institute for Infectious Disease Control, 1997.
- 186 Blumberg DA, Mink CM, Cherry JD, et al. Comparison of acellular and whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants. The APDT Vaccine Study Group. *J Pediatr* 1991;119:194–204.
- 187 Edwards KM, Karzon DT. Pertussis vaccines. *Pediatr Clin North Am* 37:549–566, 1990.
- 188 Lewis K, Cherry JD, Holroyd HJ, et al. A double-blind study comparing an acellular pertussis-component DTP vaccine with a whole-cell pertussis-component DTP vaccine in 18-month-old children. *Am J Dis Child* 1986;140:872–876.
- 189 Edwards KM, Lawrence E, Wright PF. Diphtheria, tetanus, and pertussis vaccine: a comparison of the immune response and adverse reactions to conventional and acellular pertussis components. *Am J Dis Child* 1986;140:867–871.
- 190 Edwards KM, Bradley RB, Decker MD, et al. Evaluation of a new highly purified pertussis vaccine in infants and children. *J Infect Dis* 1989;160:832–837.
- 191 Pichichero ME, Badgett JT, Rodgers Jr GC, et al. Acellular pertussis vaccine: immunogenicity and safety of an acellular pertussis vs. a whole cell pertussis vaccine

- combined with diphtheria and tetanus toxoids as a booster in 18- to 24-month-old children. *Pediatr Infect Dis J* 1987;6:352–363.
- 192 Anderson EL, Belshe RB, Bartram J. Differences in reactogenicity and antigenicity of acellular and standard pertussis vaccines combined with diphtheria and tetanus in infants. *J Infect Dis* 1988;157:731–737.
- 193 Moro PL, Perez-Vilar S, Lewis P, Bryant-Genevier M, Kamiya H, Cano M. Safety Surveillance of Diphtheria and Tetanus Toxoids and Acellular Pertussis (DTaP) Vaccines. *Pediatrics* 2018;142. pii: e20174171. doi: 10.1542/peds.2017-4171. Epub 2018 Jun 4.
- 194 Pichichero ME, Deloria MA, Rennels MB, et al. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children. *Pediatrics* 1997;100:772–788.
- 195 Pichichero ME, Edwards KM, Anderson EL, et al. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children. *Pediatrics* 2000;105:e11.
- 196 Rennels MB, Deloria MA, Pichichero ME, et al. Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines. *Pediatrics* 2000;105:e12.
- 197 Schmitt HJ, Beutel K, Schuind A, et al. Reactogenicity and immunogenicity of a booster dose of a combined diphtheria, tetanus, and tricomponent acellular pertussis vaccine at fourteen to twenty-eight months of age. *J Pediatr* 1997;130:616–623.
- 198 Liese JG, Stojanov S, Zink TH, et al. Safety and immunogenicity of Biken acellular pertussis vaccine in combination with diphtheria and tetanus toxoid as a fifth dose at four to six years of age. Munich Vaccine Study Group. *Pediatr Infect Dis J* 2001;20:981–988.

- 199 Rennels MB, Deloria MA, Pichichero ME, et al. Lack of consistent relationship between quantity of aluminum in diphtheria-tetanus-acellular pertussis vaccines and rates of extensive swelling reactions. *Vaccine* 2002;20(Suppl. 3):S44–47.
- 200 Isomura S. Efficacy and safety of acellular pertussis vaccine in Aichi Prefecture, Japan. *Pediatr Infect Dis J* 1988;7:258–262.
- 201 Blennow M, Granstrom M. Adverse reactions and serologic response to a booster dose of acellular pertussis vaccine in children immunized with acellular or whole-cell vaccine as infants. *Pediatrics* 1989;84:62–67.
- 202 Scheifele DW, Halperin SA, Ochnio JJ, et al. A modified vaccine reduces the rate of large injection site reactions to the preschool booster dose of diphtheria-tetanus-acellular pertussis vaccine: results of a randomized, controlled trial. *Pediatr Infect Dis J* 2005;24:1059–1066.
- 203 Knuf M, Habermehl P, Faber J, et al. Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life. *Vaccine* 2006;24:5627–5636.
- 204 Rennels MB, Black S, Woo EJ, et al. Safety of a fifth dose of diphtheria and tetanus toxoid and acellular pertussis vaccine in children experiencing extensive, local reactions to the fourth dose. *Pediatr Infect Dis J* 2008;27:464-465.
- 206 Keitel WA, Muenz LR, Decker MD, et al. A randomized clinical trial of acellular pertussis vaccines in healthy adults: dose-response comparisons of 5 vaccines and implications for booster immunization. *J Infect Dis* 1999;180:397–403.

- 207 Decker MD, Cates KL, Maida A. Safety and immunogenicity in adults and adolescents of Biocine acellular pertussis (aP) vaccine. In Abstracts of the 7th International Congress for Infectious Diseases, Hong Kong, June, 1996, Abstract 123.002.
- 208 Edwards KM, Decker MD, Graham BS, et al. Adult immunization with acellular pertussis vaccine. *JAMA* 1993;269:53–56.
- 209 Sekura RD, Zhang YL, Roberson R, et al. Clinical, metabolic, and antibody responses of adult volunteers to an investigational vaccine composed of pertussis toxin inactivated by hydrogen peroxide. *J Pediatr* 1988;113:806–813.
- 210 Stehr K, Lugauer S, Heninger U. Immunogenicity and reactogenicity of Lederle/Takeda acellular pertussis vaccine in 185 German adults. *Pediatr Res* 1995;37:189A.
- 211 Keitel W. Adult pertussis study results using five acellular vaccines. Acellular pertussis vaccine trials: results and impact on US public health. Presented at the National Institutes of Health Pertussis Conference. Washington, DC, June 3–5, 1996.
- 212 Ward JI, Cherry JD, Chang SJ, et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. *N Engl J Med* 2005;353:1555–1563.
- 213 Rank C, Quinn HE, McIntyre PB. pertussis vaccine effectiveness after mass immunization of high school students in Australia. *Pediatr Infect Dis* 2009;J 28:152-153.
- 214 Skoff TH, Cohn AC, Clark TA, et al. Early Impact of the US Tdap vaccination program on pertussis trends. *Arch Pediatr Adolesc Med* 2012;166:344-349.
- 215 Winter K, Harriman K, Zipprich J, et al. California pertussis epidemic, 2010. *J Pediatr* 2012;161:1091-1096.
- 216 Winter K, Glaser C, Watt J, et al. Pertussis epidemic--California, 2014. *MMWR Morb Mortal Wkly Rep* 2014;63:1129-1132

- 217 Acosta AM, DeBolt C, Tasslimi A, et al. Tdap vaccine effectiveness in adolescents during the 2012 Washington State pertussis epidemic. *Pediatrics* 135:981-989, 2015.
- 218 Liko J, Robison SG, Cieslak PR. Pertussis vaccine performance in an epidemic year- Oregon, 2012. *Clin Infect Dis* 2014;59:261-263.
- 219 Liang JL, Cocooning and Tdap vaccination, Advisory Committee on Immunization Practices, Atlanta, GA, June 25, 2015. Data source: CDC, National Notifiable Diseases Surveillance System and Supplemental Pertussis Surveillance System. To obtain slides, make request to acip@cdc.gov.
- 220 Quinn HE, Snelling TL, Habig A, et al. Parental Tdap boosters and infant pertussis: a case-control study. *Pediatrics* 2014;134:713-720.
- 221 Liko J, Robison SG, Cieslak PR. Priming with whole-cell versus acellular pertussis vaccine. *N Engl J Med* 2013;368:581-582.
- 222 Carcione D, Regan AK, Tracey L, et al. The impact of parental postpartum pertussis vaccination on infection in infants: A population-based study of cocooning in Western Australia. *Vaccine* 2015;33:5654-5661.
- 223 Urwyler P, Heininger U. Protecting newborns from pertussis - the challenge of complete cocooning. *BMC Infect Dis* 2014;14:397.
- 224 Healy CM, Rench MA, Wootton SH, et al, Evaluation of the impact of a pertussis cocooning program on infant pertussis infection. *Pediatr Infect Dis J* 2015;34:22-26.
- 225 Munoz FM, Bond NH, Maccato M, et al. Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: a randomized clinical trial. *JAMA* 2014;311:1760-1769.

- 226 Liang J, Pertussis Working Group. Overview of Tdap use during pregnancy: unpublished and recent data. Presented at the Advisory Committee on Immunization Practices, Atlanta, GA, February 23, 2011.
- 227 Amirthalingam G, Andrews N, Campbell H, et al. Effectiveness of maternal pertussis vaccination in England: an observational study. *Lancet* 2014;384:1521-1528.
- 228 Dabrera G, Amirthalingam G, Andrews N, et al. A case-control study to estimate the effectiveness of maternal pertussis vaccination in protecting newborn infants in England and Wales, 2012-2013. *Clin Infect Dis* 2015;60:333-337.
- 229 Halperin SA, Langley JM, Ye L, et al. A randomized controlled trial of the safety and immunogenicity of tetanus, diphtheria, and acellular pertussis vaccine immunization during pregnancy and subsequent infant immune response. *Clin Infect Dis* 2018;67:1063-1071. doi: 10.1093/cid/ciy244.
- 230 Skoff TH, Blain AE, Watt J, et al. Impact of the US maternal tetanus, diphtheria, and acellular pertussis vaccination program on preventing pertussis in infants <2 months of age: a case-control evaluation. *Clin Infect Dis* 2017;65:1977-1983. doi: 10.1093/cid/cix724.
- 231 Griffin JB, Yu L, Watson D, et al. Pertussis Immunisation in Pregnancy Safety (PIPS) Study: A retrospective cohort study of safety outcomes in pregnant women vaccinated with Tdap vaccine. *Vaccine* 2018;36:5173-5179. doi: 10.1016/j.vaccine.2018.07.011.
- 232 Fortner KB, Swamy GK, Broder KR, et al. Reactogenicity and immunogenicity of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant and nonpregnant women. *Vaccine* 2018;36:6354-6360. doi: 10.1016/j.vaccine.2018.07.012.

- 233 Gentile A, Juarez MDV, Lucion MF, et al. Bordetella pertussis (Bp) disease: Before (2003-2011) and after (2013-2016) maternal immunization strategy in a pediatric hospital. *Vaccine* 2018;36:1375-1380. doi: 10.1016/j.vaccine.2018.01.091.
- 234 Fernandes EG, Sato APS, Vaz-de-Lima LRA, et al. The effectiveness of maternal pertussis vaccination in protecting newborn infants in Brazil: A case-control study. *Vaccine* 2019;37:5481-5484. doi: 10.1016/j.vaccine.2019.03.049.
- 235 Hall C, Abramovitz LM, Bukowinski AT, et al. Safety of tetanus, diphtheria, and acellular pertussis vaccination among pregnant active duty U.S. military women. *Vaccine* 2020;38:1982-1988. doi: 10.1016/j.vaccine.2020.01.009.
- 236 Kerr SM, Van Bennekom CM, Mitchell AA. Tetanus, diphtheria, and pertussis vaccine (Tdap) in pregnancy and risk of major birth defects in the offspring. *Birth Defects Res* 2020;112:393-403. doi: 10.1002/bdr2.1642.
- 237 Friedrich F, Valadão MC, Brum M, et al. Impact of maternal dTpa vaccination on the incidence of pertussis in young infants. *PLoS One* 2020;15(1):e0228022. doi: 10.1371/journal.pone.0228022.
- 238 Langsam D, Anis E, Haas EJ, et al. Tdap vaccination during pregnancy interrupts a twenty-year increase in the incidence of pertussis. *Vaccine* 2020;38:2700-2706. doi: 10.1016/j.vaccine.2020.01.095.
- 239 McHugh L, Marshall HS, Perrett KP, et al. The safety of influenza and pertussis vaccination in pregnancy in a cohort of Australian mother-infant pairs, 2012-2015: The FluMum study. *Clin Infect Dis* 2019;68:402-408. doi: 10.1093/cid/ciy517.

- 240 Vygen-Bonnet S, Hellenbrand W, Garbe E, et al. Safety and effectiveness of acellular pertussis vaccination during pregnancy: a systematic review. *BMC Infect Dis* 2020;20:136. doi: 10.1186/s12879-020-4824-3.
- 241 Perrett KP, Halperin SA, Nolan T, et al. Immunogenicity, transplacental transfer of pertussis antibodies and safety following pertussis immunization during pregnancy: Evidence from a randomized, placebo-controlled trial. *Vaccine* 2020;38:2095-2104. doi: 10.1016/j.vaccine.2019.10.105.
- 242 Romanin V, Acosta AM, Juarez MDV, et al. Maternal Vaccination in Argentina: Tetanus, Diphtheria, and Acellular Pertussis Vaccine Effectiveness During Pregnancy in Preventing Pertussis in Infants <2 Months of Age. *Clin Infect Dis* 2020;70:380-387. doi: 10.1093/cid/ciz217.
- 243 Rice TF, Diavatopoulos DA, Smits GP, et al. Antibody responses to Bordetella pertussis and other childhood vaccines in infants born to mothers who received pertussis vaccine in pregnancy - a prospective, observational cohort study from the United Kingdom. *Clin Exp Immunol* 2019;197:1-10. doi: 10.1111/cei.13275.
- 244 Zimmermann P, Perrett KP, Messina NL, et al. The Effect of Maternal Immunisation During Pregnancy on Infant Vaccine Responses. *EClinicalMedicine* 2019;13:21-30. doi: 10.1016/j.eclinm.2019.06.010.
- 245 World Health Organization. WHO vaccine-preventable diseases: monitoring system. 2019 global summary. Available at https://apps.who.int/immunization_monitoring/globalsummary/schedules. Accessed April 25, 2020.

- 246 Mazzilli S, Tivoschi L, Lopalco PL. Tdap vaccination during pregnancy to protect newborns from pertussis infection. *Ann Ig*. 2018 Jul-Aug;30(4):346-363. doi: 10.7416/ai.2018.2226.
- 247 Pichichero ME, DeTora LM, Johnson D. An adolescent and adult formulation combined tetanus, diphtheria and five-component pertussis vaccine. *Vaccine* 2006;5:175–187.
- 248 Pichichero ME, Blatter M, Kennedy WA, et al. Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents. *Pediatrics* 2006;117:1084–1093.
- 249 Pichichero ME, Rennels MB, Edwards KM, et al. Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults. *JAMA* 2005;293:3003–3011.
- 250 Talbot EA, Brown KH, Kirkland KB, et al. The safety of immunizing with tetanus-diphtheria-acellular pertussis vaccine (Tdap) less than 2 years following previous tetanus vaccination: experience during a mass vaccination campaign of healthcare personnel during a respiratory illness outbreak. *Vaccine* 2010;28:8001–8007.
- 251 Klein NP, Hansen J, Lewis E, et al. Post-marketing safety evaluation of a tetanus toxoid, reduced diphtheria toxoid and 3-component acellular pertussis vaccine administered to a cohort of adolescents in a United States health maintenance organization. *Pediatr Infect Dis J* 2010;29:613–617.
- 252 Yih WK, Nordin JD, Kulldorff M, et al. An assessment of the safety of adolescent and adult tetanus-diphtheria-acellular pertussis (Tdap) vaccine, using active surveillance for adverse events in the Vaccine Safety Datalink. *Vaccine* 2009;27:4257–4262.

- 253 Halperin S. How soon after a prior tetanus-diphtheria vaccination can one give adult formulation tetanus-diphtheria-acellular pertussis vaccine? *Pediatr Infect Dis* 2006;25:195–200.
- 254 Koepke R, Eickhoff JC, Ayele RA, et al. Estimating the effectiveness of tetanus-diphtheria-acellular pertussis vaccine (Tdap) for preventing pertussis: evidence of rapidly waning immunity and difference in effectiveness by Tdap brand. *J Infect Dis*. 2014;210:942-953.
- 255 Worby CJ, Kenyon C, Lynfield R, et al. Examining the role of different age groups, and of vaccination during the 2012 Minnesota pertussis outbreak. *Sci Rep* 2015;17:13182.
- 256 Witt MA, Arias L, Katz PH, et al. Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine compared to recipients of acellular pertussis vaccines in a large US cohort. *Clin Infect Dis* 2013;56:1248-1254.
- 257 Australian Government Department of Health. National Notifiable Diseases Surveillance System: Notifications of a selected disease by age group, sex and year. Available at http://www9.health.gov.au/cda/source/rpt_5_sel.cfm. Accessed April 25, 2020.
- 258 Sheridan SL, McCall BJ, Davis CA, et al. Acellular pertussis vaccine effectiveness for children during the 2009-2010 pertussis epidemic in Queensland. *Med J Aust* 2014;200:334-338.
- 259 Sheridan SL, Ware RS, Grimwood K, et al. Number and order of whole cell pertussis vaccines in infancy and disease protection. *JAMA* 2012;308:454-456.
- 260 Centers for Disease Control and Prevention. Pertussis epidemic Washington, 2012. *MMWR Morbid Mortal Wkly Rep* 2012;61:517-522.

- 261 State of Wisconsin, Department of Health Services. Annual Summary of Reported Pertussis, 2012. Available from: <https://www.dhs.wisconsin.gov/immunization/2012asrpertussis.pdf>. Accessed April 25, 2020.
- 262 Centers for Disease Control and Prevention. Pertussis cases by year (1922-2013). Available from: www.cdc.gov/pertussis/surv-reporting/cases-by-year.html. Access date, October 2015.
- 263 Klein NP, Bartlett J, Rowhani-Rahbar A, et al. Waning protection after fifth dose of acellular pertussis vaccine in children. *N Engl J Med* 2012;367:1012-1019.
- 264 Baxter R, Bartlett J, Rowhani-Rahbar A, et al. Effectiveness of pertussis vaccines for adolescents and adults: case-control study. *BMJ* 2013;347:f4249
- 265 Decker MD, Hosbach P, Johnson DR, et al. Estimating the effectiveness of tetanus-diphtheria-acellular pertussis vaccine. *J Infect Dis* 2015;211:497-498.
- 266 Sanstead E, Kenyon C, Rowley S, et al. Understanding trends in pertussis incidence: an agent-based model approach. *Am J Public Health* 2015;105:e42-47.
- 267 Kiraly N, Dharmage SC, Allen KJ. Reduced risk of pertussis among persons ever vaccinated with whole-cell pertussis vaccine compared to recipients of acellular pertussis vaccines may have been confounded by age. *Clin Infect Dis* 2013;57:770.
- 268 André P, Johnson DR, Greenberg DP, et al. Reduced risk of pertussis in whole-cell compared to acellular vaccine recipients is not supported when data are stratified by age. *Clin Infect Dis* 2013;57:1658-1660.
- 269 Klein NP, Bartlett J, Fireman B, et al. Comparative effectiveness of acellular versus whole-cell pertussis vaccines in teenagers. *Pediatrics* 2013;131:e1716-1722.

- 270 Sheridan SL, Frith K, Snelling TL, et al. Waning vaccine immunity in teenagers primed with whole cell and acellular pertussis vaccine: recent epidemiology. *Expert Rev Vaccines* 2014;13:1081-1106.
- 271 Gambhir M1, Clark TA2, Cauchemez S, et al. A change in vaccine efficacy and duration of protection explains recent rises in pertussis incidence in the United States. *PLoS Comput Biol* 2015;11:e1004138.
- 272 Ntezayabo B, De Serres G, Duval B. pertussis resurgence in Canada largely caused by a cohort effect. *Pediatr Infect Dis J* 2003;22:22-27.
- 273 Rendi-Wagner P, Kundi M, Mikolasek A, Vécsei A, Frühwirth M, Kollaritsch H. Hospital-based active surveillance of childhood pertussis in Austria from 1996 to 2003: estimates of incidence and vaccine effectiveness of whole-cell and acellular vaccine. *Vaccine* 2006;24:5960-5.
- 274 Zerbo O, Bartlett J, Goddard K, Fireman B, Lewis E, Klein NP. Acellular pertussis vaccine effectiveness over time. *Pediatrics* 2019;144. pii: e20183466. doi: 10.1542/peds.2018-3466. Epub 2019 Jun 10.
- 275 Mahmud AS, Lipsitch M, Goldstein E. On the role of different age groups during pertussis epidemics in California, 2010 and 2014. *Epidemiol Infect* 2019;147:e184. doi: 10.1017/S0950268819000761.
- 276 Brummelman J, Wilk MM, Han WG, et al. Roads to the development of improved pertussis vaccines paved by immunology. *FEMS Pathogens and Disease* 2015;73:ftv067.
- 277 Ross PJ, Sutton CE, Higgins S, et al. Relative contribution of Th1 and Th17 cells in adaptive immunity to *Bordetella pertussis*: towards the rational design of an improved acellular pertussis vaccine. *PLoS Pathog* 2013;9:e1003264.

- 278 da Silva Antunes R, Babor M, Carpenter C, et al. Th1/Th17 polarization persists following whole-cell pertussis vaccination despite repeated acellular boosters. *J Clin Invest* 2018;128:3853-3865. doi: 10.1172/JCI121309.
- 279 Plotkin SA. Composition of pertussis vaccine given to infants determines long-term T cell polarization. *J Clin Invest* 2018;128:3742-3744. doi: 10.1172/JCI122726.
- 280 Mills KH, Gerdt V. Mouse and pig models for studies of natural and vaccine-induced immunity to *Bordetella pertussis*. *J Infect Dis* 2014;209 Suppl 1:S16-9. doi: 10.1093/infdis/jit488.
- 281 Wilk MM, Borkner L, Misiak A, Curham L, Allen AC, Mills KHG. Immunization with whole cell but not acellular pertussis vaccines primes CD4 TRM cells that sustain protective immunity against nasal colonization with *Bordetella pertussis*. *Emerg Microbes Infect* 2019;8:169-185. doi: 10.1080/22221751.2018.1564630.
- 282 Solans L, Debrie AS, Borkner L, et al. IL-17-dependent SIgA-mediated protection against nasal *Bordetella pertussis* infection by live attenuated BPZE1 vaccine. *Mucosal Immunol* 2018;11:1753-1762. doi: 10.1038/s41385-018-0073-9.
- 283 Pinto MV, Merkel TJ. Pertussis disease and transmission and host responses: insights from the baboon model of pertussis. *J Infect* 2017;74 Suppl 1:S114-S119. doi: 10.1016/S0163-4453(17)30201-3.
- 284 Misegades LK, Winter K, Harriman K, et al. Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010. *JAMA* 2012;308:2126-2132.

- 285 Goldstein E, Worby CJ, Lipsitch M. On the role of different age groups and pertussis vaccines during the 2012 outbreak in Wisconsin. *Open Forum Infect Dis* 2018;5:ofy082. doi: 10.1093/ofid/ofy082.
- 286 World Health Organization. WHO recommendations for routine immunization - summary tables. Available at https://www.who.int/immunization/policy/immunization_tables/en/. Accessed April 25, 2020.
- 287 World Health Organization. Immunization, Vaccines and Biologicals: Data, statistics and graphics. Available at https://apps.who.int/immunization_monitoring/surveillance/data/en. Accessed April 25, 2020.
- 288 Liang JL, Tiwari T, Moro P, et al. Prevention of pertussis, tetanus, and diphtheria with vaccines in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep* 2018; 67:1–44.
- 289 Tessier E, Campbell H, Ribiero S, et al. Impact of extending the timing of maternal pertussis vaccination on hospitalized infant pertussis in England, 2014 - 2018. *Clin Infect Dis* 2020, in press.
- 290 Hoffman J. How anti-vaccine sentiment took hold in the United States. *The New York Times*. 2019 Sep 23. Available at <https://www.nytimes.com/2019/09/23/health/anti-vaccination-movement-us.html>. Accessed April 22, 2020.
- 291 Godlee F, Smith J, Marcovitch H. Wakefield's article linking MMR vaccine and autism was fraudulent. *BMJ* 2011;342:c7452. doi: 10.1136/bmj.c7452.

- 292 Phadke VK, Bednarczyk RA, Salmon DA, Omer SB. Association Between Vaccine Refusal and Vaccine-Preventable Diseases in the United States: A Review of Measles and Pertussis. *JAMA* 2016;315):1149-58. doi: 10.1001/jama.2016.1353
- 293 Glanz JM, McClure DL, Magid DJ, Daley MF, France EK, Salmon DA, Hambidge SJ. Parental refusal of pertussis vaccination is associated with an increased risk of pertussis infection in children. *Pediatrics* 2009;123:1446-51. doi: 10.1542/peds.2008-2150.
- 294 Glanz JM, Narwaney KJ, Newcomer SR, et al. Association between undervaccination with diphtheria, tetanus toxoids, and acellular pertussis (DTaP) vaccine and risk of pertussis infection in children 3 to 36 months of age. *JAMA Pediatr* 2013;167:1060-4. doi: 10.1001/jamapediatrics.2013.2353.
- 295 Gershon AA, Edwards K, Orenstein W, Schaffner W. Freedom, measles, and freedom from measles. *N Engl J Med* 2020;382:983-985. doi: 10.1056/NEJMp2000807.
- 296 Loch C, Mielcarek N. Live attenuated vaccines against pertussis. *Expert Rev Vaccines* 2014;13:1147-1158.
- 297 Mielcarek N, Debie AS, Raze D, et al. Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough. *PLoS Pathog* 2006;2:e65.
- 298 Feunou PF, Kammoun H, Debie AS, et al. Long-term immunity against pertussis induced by a single nasal administration of live attenuated B. pertussis BPZE1. *Vaccine* 2010;28:7047-7053.
- 299 Kammoun H, Feunou PF, Foligne B, et al. Dual mechanism of protection by live attenuated *Bordetella pertussis* BPZE1 against *Bordetella bronchiseptica* in mice. *Vaccine* 2012;30:5864– 5870.

- 300 Skerry CM, Mahon BP. A live, attenuated *Bordetella pertussis* vaccine provides long-term protection against virulent challenge in a murine model. *Clin Vaccine Immunol* 2011;18:187-193.
- 301 Feunou PF, Kammoun H, Debie AS, et al. Heterologous prime-boost immunization with live attenuated *B. pertussis* BPZE1 followed by acellular pertussis vaccine in mice. *Vaccine* 2014;32:4281-4288.
- 302 Jahnmatz M, Amu S, Ljungman M, et al. B-cell responses after intranasal vaccination with the novel attenuated *Bordetella pertussis* vaccine strain BPZE1 in a randomized phase I clinical trial. *Vaccine* 2014;32:3350-3356.
- 303 US National Library of Medicine. ClinicalTrials.gov. Study of BPZE1 (High Dose) nasal live attenuated *B. pertussis* vaccine. Available at <https://clinicaltrials.gov/ct2/results?term=NCT02453048&Search=Search>. Accessed April 25, 2020.
- 304 Allen AC, Wilk MM, Misiak A, Borkner L, Murphy D, Mills KHG. Sustained protective immunity against *Bordetella pertussis* nasal colonization by intranasal immunization with a vaccine-adjuvant combination that induces IL-17-secreting TRM cells. *Mucosal Immunol* 2018;11:1763-1776. doi: 10.1038/s41385-018-0080-x.
- 305 Locht C, Papin JF, Lecher S, et al. Live attenuated pertussis vaccine BPZE1 protects baboons against *Bordetella pertussis* disease and infection. *J Infect Dis* 2017;216:117-124. doi: 10.1093/infdis/jix254.
- 306 Debie AS, Coutte L, Raze D, et al. Construction and evaluation of *Bordetella pertussis* live attenuated vaccine strain BPZE1 producing Fim3. *Vaccine* 2018;36:1345-1352. doi: 10.1016/j.vaccine.2018.02.017.

- 307 Debie AS, Mielcarek N, Lecher S, Roux X, Sirard JC, Loch C. Early Protection against Pertussis Induced by Live Attenuated *Bordetella pertussis* BPZE1 Depends on TLR4. *J Immunol* 2019;203:3293-3300. doi: 10.4049/jimmunol.1901102.
- 308 Lin A, Apostolovic D, Jahnmatz M, et al. Live attenuated pertussis vaccine BPZE1 induces a broad antibody response in humans. *J Clin Invest* 2020 Mar 23. pii: 135020. doi: 10.1172/JCI135020.
- 309 Thorstensson R, Trollfors B, Al-Tawil N, et al. A phase I clinical study of a live attenuated *Bordetella pertussis* vaccine--BPZE1; a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers. *PLoS One* 2014;9:e83449. doi: 10.1371/journal.pone.008344.
- 310 Loch C, Mielcarek N. New pertussis vaccination approaches: en route to protect newborns? *FEMS Immunol Med Microbiol* 2012;66:121–133,.
- 311 Gracia A, Polewicz M, Halperin SA, et al. Antibody responses in adult and neonatal BALB/c mice to immunization with novel *Bordetella pertussis* vaccine formulations. *Vaccine* 2011;29:1595–1604.
- 312 Asokanathan C, Corbel M, Xing D. A CpG-containing oligodeoxynucleotide adjuvant for acellular pertussis vaccine improves the protective response against *Bordetella pertussis*. *Hum Vaccin Immunother* 2013;9:325-331.
- 313 Sharma S, Benson HA, Mukkur TK, et al. Preliminary studies on the development of IgA-loaded chitosan-dextran sulphate nanoparticles as a potential nasal delivery system for protein antigens. *J Microencapsul* 2013;30:283-294.
- 314 Alvarez Hayes J, Erben E, Lamberti Y, et al. Identification of a new protective antigen of *Bordetella pertussis*. *Vaccine* 2011;29:8731-8739.

- 315 Alvarez Hayes J, Erben E, Lamberti Y, et al. Bordetella pertussis iron regulated proteins as potential vaccine components. *Vaccine* 2013;31:3543-3548.
- 316 Cheung GY, Xing D, Prior S, et al. Effect of different forms of adenylate cyclase toxin of Bordetella pertussis on protection afforded by an acellular pertussis vaccine in a murine model. *Infect Immun* 2006;74:6797-6805.
- 317 Asensio CJ, Gaillard ME, et al. Outer membrane vesicles obtained from Bordetella pertussis Tohama expressing the lipid A deacylase PagL as a novel acellular vaccine candidate. *Vaccine* 2011;29:1649-1656.
- 318 Roberts R, Moreno G, Bottero D, et al. Outer membrane vesicles as acellular vaccine against pertussis. *Vaccine* 2008;26:4639-4646.
- 319 de Gouw D, Serra DO, de Jonge MI, et al. The vaccine potential of Bordetella pertussis biofilm-derived membrane proteins. *Emerg Microbes Infect* 2014;3:e58.
- 320 Robbins JB, Schneerson R, Kubler-Kielb J, et al. Toward a new vaccine for pertussis. *Proc Natl Acad Sci* 2014;111:3213-3216.
- 321 Buasri W, Impoolsup A, Boonchird C, et al. Construction of Bordetella pertussis strains with enhanced production of genetically-inactivated Pertussis Toxin and Pertactin by unmarked allelic exchange. *BMC Microbiol* 2012;12:61.
- 322 Hozbor DF. Outer membrane vesicles: an attractive candidate for pertussis vaccines. *Expert Rev Vaccines* 2017;16:193-196. doi: 10.1080/14760584.2017.1276832.
- 323 Zurita ME, Wilk MM, Carriquiriborde F, et al. A pertussis outer membrane vesicle-based vaccine induces lung-resident memory CD4 T cells and protection against Bordetella pertussis, including pertactin deficient strains. *Front Cell Infect Microbiol* 2019;9:125. doi: 10.3389/fcimb.2019.00125.

- 324 Dorji D, Mooi F, Yantorno O, Deora R, Graham RM, Mukkur TK. Bordetella Pertussis virulence factors in the continuing evolution of whooping cough vaccines for improved performance. *Med Microbiol Immunol* 2018;207:3-26. doi: 10.1007/s00430-017-0524-z.
- 325 Boehm DT, Hall JM, Wong TY, et al. Evaluation of adenylate cyclase toxoid antigen in acellular pertussis vaccines by using a Bordetella pertussis challenge model in mice. *Infect Immun* 2018;86. pii: e00857-17. doi: 10.1128/IAI.00857-17.
- 326 Nguyen AW, Wagner EK, Laber JR, et al. A cocktail of humanized anti-pertussis toxin antibodies limits disease in murine and baboon models of whooping cough. *Sci Transl Med* 2015;7:316ra195. doi: 10.1126/scitranslmed.aad0966.
- 327 Garlapati S, Eng NF, Kiros TG et al. Immunization with PCEP microparticles containing pertussis toxoid, CpG ODN and a synthetic innate defense regulator peptide induces protective immunity against pertussis. *Vaccine* 2011;29:6540–6548.
- 328 Allen AC, Mills KH. Improved pertussis vaccines based on adjuvants that induce cell-mediated immunity. *Expert Rev Vaccines* 2014;13:1253-1264.
- 329 Agnolon V, Bruno C, Leuzzi R, et al. The potential of adjuvants to improve immune responses against Tdap vaccines: A preclinical evaluation of MF59 and monophosphoryl lipid A. *Int J Pharm* 2015;492:169-176.
- 330 Misiak A, Leuzzi R, Allen AC, et al. Addition of a TLR7 agonist to an acellular pertussis vaccine enhances Th1 and Th17 responses and protective immunity in a mouse model. *Vaccine* 2017;35:5256-5263. doi: 10.1016/j.vaccine.2017.08.009.
- 331 Jennings-Gee J, Quataert S, Ganguly T, D'Agostino R Jr, Deora R, Dubey P. The adjuvant Bordetella Colonization Factor A attenuates alum-induced Th2 responses and

enhances *Bordetella pertussis* clearance from mouse lungs. *Infect Immun* 2018;86. pii: e00935-17. doi: 10.1128/IAI.00935-17.

332 Atwell JE, Van Otterloo J, Zipprich J, et al. Nonmedical vaccine exemptions and pertussis in California, 2010. *Pediatrics* 2013;132:624-630.